Acasti Pharma Awarded Broad Composition-ofMatter and Method of Use Patents by the European Patent Office

Laval, Québec, CANA9A, January 9, 2019 — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ:
ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced a Certificate for a European Patent has been issued by the European Patent Office. The granted patent is valid until 2030 and relates to a concentrated phospholipid composition and method of using the same for modulating blood lipids. This patent was validated in Belgium, Switzerland, Germany, Denmark,
Spain, Finland, France, United Kingdom, Italy, Netherlands, Norway, Portugal and Sweden.

Pierre Lemieux, Ph.D., COO and CSO of Acasti, commented, “This is an important milestone for Acasti, as the allowance of a patent in a major jurisdiction such as Europe further strengthens and expands the Company’s intellectual property portfolio. This patent contains broad claims, and provides us now with uniform protection across all major markets in Europe. Furthermore, it strengthens the Company’s strategic position, which could support valuable commercial opportunities for the Company.”

Jan D’Alvise, president and CEO of Acasti, commented, “We are very pleased to receive confirmation of the issuance of our important European patent. This constitutes a key milestone achieved in the Company’s intellectual property strategy as we continue our efforts to complete the TRILOGY Phase 3 clinical trials for CaPre, our proprietary therapeutic omega-3/phospholipid drug candidate. We believe CaPre has the potential to become best-inclass and could address the market need for an effective, safe and efficiently absorbed drug for the treatment of cardiometabolic related diseases.”

SOURCE:

https://www.acastipharma.com/wp-content/uploads/ACST-Press-release-EU-patent-Final4docx.pdf

You Might Also Like